English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Muscular Dystrophy during Osteoarthritic Disorder (MD-OAD) is a group of disorders characterized by muscle wasting, weakness and degeneration along with potential loss of joint cartilage, bone hypertrophy, painful Joint effusion and restricted movement of joints. Creatine Kinase-Muscle (CK-MM) and AldolaseA (AldoA) are considered to be realistic biomarkers to detect the MD-OAD. The aim of the study was to evaluate the serum levels of CK-MM and AldoA and determine their correlation with risk factors such as muscle weakness, muscle degeneration, skeletal muscle damage resulting in deranged anatomical features developed in MD-OAD. Methods: Baseline data from 162 patients, aged 59.89±7.19 years, suffering with MD-OADs for 7.89±1.90 years and 153 participants, aged 58.96±8.63 years, without MD-OADs were collected in this crosssectional study. Separate analyses were performed for participants with and without MD-OAD symptoms confirming with electromyography, musculoskeletal ultrasound, muscle biopsy, CT-scan and MRI. Serum CK-MM and AldoA levels were estimated. All subjects, with and without MD-OADs, underwent standardized physical, radiographic, other related examinations and completed a questionnaire. Results: The levels of CK-MM and AldoA of experimental subjects, representing the risk factor of MD-OADs, were increased their mean±SD values 248.42±100.96 and 8.87±2.70 U/L respectively and abnormal anatomical features, pain syndromes and obesity were all exhibited highly significant differences (p<0.0001) when compared with the control subjects. Conclusion: It is firmly concluded that monitoring the levels of serum CK-MM and AldoA along with anatomical parameters features, pain free life-style and body weight, even at early progressive stage, may be effective diagnostic protocol for detecting MD-OAD.

Muscular Dystrophy during Osteoarthritic Disorder: A Novel Diagnostic Protocol Evidenced by Biochemical and Anatomical Parameters